Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-03-03
1999-11-02
Mach, D. Margaret
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
546340, 546344, A01N 4366, C07D21170, C07D21172
Patent
active
059771054
DESCRIPTION:
BRIEF SUMMARY
This invention relates to pharmaceutically useful compounds, their use as medicaments, pharmaceutical formulations including them and methods for their preparation.
European Patent Applications EP-A-0 264 114 and EP-A-0 267 439 disclose certain phenylalkyl- and phenylalkoxypyridine alkanol derivatives and their use as platelet-activating factor (PAF) antagonists. Example 11 of EP-A-0 267 439 (G. D. Searle & Co.) shows .alpha.-[3-(4-methoxyphenyl)ethyl]-3-pyridinepropanol: ##STR2##
According to the present invention, there is provided a compound of formula I, ##STR3## wherein--X represents (CH.sub.2).sub.n O, (CH.sub.2).sub.n S or C.sub.2 alkylene; latter two groups may be substituted by one or more substituents selected from chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, C(O)R.sup.2, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), pyridyl, thiazinyl, phenyl or C.sub.7-9 alkylphenyl which latter two groups are optionally substituted by one or more substituent selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 and SO.sub.2 NR.sup.17 R.sup.18 ; (optionally substituted by one or more fluorine atoms), C.sub.7-9 alkylphenyl or phenyl, which latter group is optionally substituted by hydroxy; and R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20 and R.sup.21 independently represent H, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms) or phenyl; atoms; represent phenyl or phenyl substituted with one or more substituents OR.sup.1, in which R.sup.1 represents C.sub.1-10 alkyl;
or a pharmaceutically acceptable derivative thereof, hereinafter referred to together as "the compounds of the invention".
We prefer X to represent CH.sub.2 O, CH.sub.2 S or C.sub.2 alkylene and Ar.sup.1 to represent-- from chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, and C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms); or more substituents selected from chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21 and C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), and on the ring remote from X by one or more substituent selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), C(O)R.sup.4, C(O)OR.sup.5 C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 and SO.sub.2 NR.sup.17 R.sup.18.
Pharmaceutically acceptable derivatives include solvates and salts. Particular salts which may be mentioned include hydrochloride, hydrobromide, sulfonate, tosylate methanesulfonate and oxalate.
Alkylene groups which X may represent and the alkyl portion of alkylphenyl groups which R.sup.1, R.sup.2 and R.sup.3 may represent may be saturated or unsaturated. Alkylphenyl groups are attached via the alkyl part of the group to the rest of the compound (and may be unsaturated or interrupted by one or more oxygen atoms), as distinct from phenyl substituted by alkyl. Alkyl groups which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, R.sup.20 and R.sup.21 may represent or which may be substituted on one or more of the aromatic rings forming part of Ar.sup.1 may be saturated or unsaturated, straight-chain or branched, and cyclic or acyclic (including alkyl groups substituted with a cycloalkyl group such as cyclopropylmethyl).
According to the invention there is also provided a process for the preparation of compounds of formula I as hereinbefore defined which comprises:
(a) reduction of a corresponding compound of formula II, ##STR4##
wherein X.sup.a represents (CH.
Cheshire David
Cladingboel David
Hardern David
Stocks Michael
Astra Pharmaeuticals Ltd.
Mach D. Margaret
LandOfFree
Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2135703